Topiramate, sold under the brand name Topamax, consistently produces weight loss in clinical trials, typically in the range of 5 to 10 percent of body weight over a year depending on dose. It was originally approved as an anti-seizure medication and later for migraine prevention, but its weight-reducing effect has made it one of the more widely discussed off-label options for obesity. The story is more complicated than “take Topamax, lose weight,” though, because the drug comes with a distinct set of cognitive and metabolic side effects that make the trade-off worth understanding before you or your doctor consider it.
How Much Weight You Can Expect to Lose
A large randomized, placebo-controlled trial lasting 60 weeks tested three doses of topiramate against placebo in obese adults. People on placebo lost about 1.7% of their starting weight. Those on 96 mg per day lost 7.0%, those on 192 mg lost 9.1%, and the highest-dose group at 256 mg lost 9.7%. More than half the people in each topiramate group lost at least 5% of their body weight, compared with only 18% on placebo. Roughly 29 to 44% of people on topiramate hit the 10% threshold, versus just 6% on placebo.1International Journal of Obesity. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
A separate meta-analysis focused on people with type 2 diabetes found that topiramate reduced weight by an average of 3.4 kg more than placebo, along with meaningful drops in blood sugar and BMI.2PubMed. Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis So the effect is real and reproducible, though it is clearly dose-dependent: higher doses produce more weight loss, but they also produce more side effects.
Why Topiramate Causes Weight Loss
Researchers still do not have a single, tidy explanation for topiramate’s weight-loss effect, which is partly why it took so long for the drug to be formally incorporated into obesity treatment. Several mechanisms appear to work in parallel.
One involves appetite regulation in the brain. Recent research shows that topiramate inhibits hunger-promoting neurons by enhancing signaling through a specific type of receptor and potassium channels, effectively turning down the brain’s “eat more” signal. Interestingly, this effect does not work through the receptor type most commonly associated with the drug’s anti-seizure activity.3PubMed Central. Topiramate Enhances GABAergic Tone to Orexigenic Neuropeptide Y/Agouti‐Related Peptide (NPY/AgRP) Neurons
Another mechanism involves carbonic anhydrase, an enzyme family involved in fat production. Topiramate is a strong inhibitor of certain carbonic anhydrase forms that participate in the chemical steps cells use to build new fat molecules. This inhibition may reduce the body’s ability to create and store fat.4PubMed. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity Researchers have proposed that designing drugs specifically targeting the carbonic anhydrase forms involved in fat synthesis, using topiramate as a starting point, could lead to more targeted obesity treatments in the future.5Current Pharmaceutical Design. Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs?
Many people on topiramate simply report feeling less hungry and getting full faster. Some also experience changes in taste perception, which may contribute indirectly. The drug appears to alter how carbonated beverages taste, making them seem flat and unappealing.6PubMed. Carbonation dysgeusia associated with topiramate If your go-to comfort drink is soda or beer, suddenly finding it unpleasant could cut a meaningful number of calories without any conscious effort.
The Cognitive Side Effects People Worry About
The most talked-about downside of topiramate is what patients sometimes call “dopamax brain.” The drug can impair working memory, word-finding, and concentration. This is not anecdotal folklore. A randomized, double-blind study tested cognitive performance at several dose levels and found clear dose-dependent declines. At 192 mg per day, 15% of subjects showed measurable cognitive worsening, and at 384 mg that number jumped to 35%, compared with just 5% on placebo.7PubMed Central. Topiramate dose effects on cognition: a randomized double-blind study
Another study found that each unit increase in topiramate blood levels predicted a roughly 3.6% drop in working memory accuracy, and at the average concentration seen four hours after dosing, the expected decline was about 9%.8PubMed Central. Severity of Topiramate-Related Working Memory Impairment is Modulated by Plasma Concentration and Working Memory Capacity For someone whose job depends on sharp recall or quick verbal processing, this can be a dealbreaker.
A review of the available evidence noted that up to 10% of patients complain of cognitive side effects, that these problems tend to appear within the first six weeks of treatment, and that they are dose-dependent. Slower titration schedules and keeping doses as low as possible reduce the risk.9PubMed Central. Topiramate and cognitive impairment: evidence and clinical implications The practical takeaway is that if you are trying topiramate for weight loss and your doctor starts you at a low dose with gradual increases, that is not just caution for caution’s sake. It meaningfully reduces the chance of walking around in a fog.
Kidney Stones and Metabolic Acidosis
The same carbonic anhydrase inhibition that may help with weight loss creates a separate problem: it changes your urine chemistry. Topiramate reduces the kidneys’ ability to properly acidify urine and can lower citrate levels, sometimes to undetectable amounts. Low urinary citrate is a major risk factor for calcium-based kidney stones. The rate of kidney stones in people on topiramate is two to four times higher than in the general population.10PubMed. Topiramate increases biochemical risk of nephrolithiasis
Long-term use can also cause a persistent low-grade metabolic acidosis, where the blood becomes slightly more acidic than it should be. A case study documented both metabolic acidosis and subsequent kidney stone formation in a patient on long-term topiramate.11PubMed Central. Topiramate induced metabolic acidosis and kidney stones – a case study If you are on topiramate for an extended period, staying well-hydrated matters more than usual, and periodic blood and urine checks can catch these problems before they become painful.
The Combination With Phentermine
Topiramate’s most formal role in obesity treatment is not as a solo drug but as half of a combination pill with phentermine, marketed as Qsymia. The combination was approved in the United States in 2012, and it produces more weight loss than either drug alone.12PubMed Central. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity Phentermine is a stimulant that suppresses appetite; topiramate adds its own appetite-reducing and metabolic effects on top.
In the EQUIP trial, a large phase 3 study, the higher-dose combination (phentermine 15 mg plus topiramate 92 mg) produced an average weight loss of about 10.2 kg over 56 weeks, compared with 1.4 kg for placebo. Seventy percent of people on the higher dose lost at least 5% of their body weight, and 48% lost at least 10%.13The Lancet. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (EQUIP): a randomised, placebo-controlled, phase 3 trial These numbers are substantially better than topiramate alone, though still well below what newer injectable drugs achieve.
How Topiramate Compares to Newer Weight-Loss Drugs
The obesity treatment landscape shifted dramatically with the arrival of GLP-1 receptor agonists. Semaglutide at the 2.4 mg weekly injection dose produces average weight loss of about 15% at one year, roughly double what topiramate alone achieves and notably more than the phentermine-topiramate combination. A review of obesity medications characterized older agents including phentermine-topiramate as producing “only modest additional weight loss” compared with lifestyle changes alone, while semaglutide represented a clear step up.14PubMed. Drugs for Treating Obesity
But there is a catch: cost. A cost-effectiveness analysis found that phentermine-topiramate was the lowest-cost treatment option with nearly identical quality-adjusted outcomes to more expensive drugs. Injectable GLP-1 agonists like liraglutide and semaglutide were dominated by or vastly more expensive than phentermine-topiramate per unit of benefit gained.15PubMed. Cost-effectiveness analysis of five anti-obesity medications from a US payer’s perspective A separate analysis in adolescents with severe obesity found that phentermine-topiramate cost about $6,921 more than no treatment while semaglutide cost an additional $84,649 beyond that, with relatively small additional benefit in quality-adjusted life years.16JAMA Network Open. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity For people without insurance coverage for newer agents, topiramate or its combination product remains a financially accessible option.
Binge Eating and Bulimia
One area where topiramate has shown particular promise is in eating disorders that involve binge episodes. In a randomized trial of people with binge eating disorder and obesity, topiramate reduced binge frequency by 94% compared with 46% for placebo. People who completed the study lost an average of 5.9 kg.17PubMed. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial A review of the evidence called topiramate a “relatively safe and effective treatment for obese subjects with binge eating disorder,” though the data was still considered preliminary at the time.18PubMed Central. Treatment of obese patients with binge eating disorder using topiramate: a review
In bulimia nervosa, a randomized trial found that topiramate achieved a greater-than-50% reduction in binging and purging in about 37% of patients, compared with 3% on placebo, along with about 3.8 kg more weight loss than the control group.19PubMed. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial For people whose weight issues are intertwined with compulsive overeating, topiramate addresses both the behavior and the weight simultaneously, which is a meaningful advantage over drugs that only reduce appetite.
What Happens When You Stop
This is where many people get disappointed. A prospective study of migraine patients who had lost weight on topiramate found that after discontinuation, body weight showed a clear trend back up, with 27 patients in the cohort returning to their pre-topiramate weight. The only factor that predicted who would regain weight was a measure of insulin resistance before starting the drug: people who were more insulin-resistant before treatment were more likely to regain everything.20PubMed. Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study
This pattern is not unique to topiramate. Weight regain after stopping obesity medications is the norm, not the exception, across virtually every drug class. The body’s weight-regulation systems tend to push back toward the pre-treatment set point once the pharmacological pressure is removed. It is worth knowing this upfront: topiramate is not a “course of treatment” you finish and then maintain results. If the drug is working and you tolerate it, the implicit plan is usually long-term use or a transition to another strategy before stopping.
Real-World Sticking Power
Clinical trials select for motivated participants and provide regular follow-up, so the picture in everyday practice tends to be less rosy. A systematic review of real-world outcomes with anti-obesity medications found a general pattern of poor adherence and persistence across all the drugs studied.21PubMed Central. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review
A real-world study of over 26,000 patients newly prescribed various obesity medications found that at six months, only about 27% of people on phentermine-topiramate were still filling their prescriptions, compared to about 42% for liraglutide. After adjusting for baseline differences, people on phentermine-topiramate had a significantly higher risk of discontinuation than those on liraglutide, though they fared somewhat better than those on lorcaserin or naltrexone-bupropion.22PubMed. Persistence of newer anti-obesity medications in a real-world setting Side effects, and especially the cognitive ones, are a major reason people stop. The gap between what the drug can do in a trial and what it actually does in the real world is substantial.
Pregnancy Risk
This is one area where the evidence is serious enough that it should factor into prescribing decisions for anyone who could become pregnant. A large pregnancy cohort study found that the risk of oral clefts (cleft lip or cleft palate) was 4.1 per 1,000 births among women exposed to topiramate in the first trimester, compared with 1.1 per 1,000 in unexposed women. The risk was especially pronounced at doses above 100 mg per day, where it was roughly five times higher than background. Women with epilepsy, who tended to take higher doses, faced even steeper risk.23PubMed Central. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study
A separate pooled analysis from birth defect surveillance programs estimated the odds of cleft lip or palate at about five times higher with first-trimester topiramate exposure, while finding no increase in overall major birth defects.24PubMed Central. Use of topiramate in pregnancy and risk of oral clefts For someone taking topiramate specifically for weight loss rather than for seizures, where the benefit-risk calculation is more straightforward, reliable contraception while on the drug is not optional advice. It is essential.
Topiramate and Psychiatric Medications
Many people who might benefit from topiramate’s weight-loss effects are already taking psychiatric medications that cause weight gain, particularly antipsychotics like olanzapine and risperidone. A meta-analysis of randomized controlled trials found that adding topiramate to antipsychotic treatment in people with schizophrenia produced significant reductions in both body weight and BMI, with no worsening of psychiatric symptoms and no difference in overall side effects between the topiramate and control groups.25PubMed. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials
In a trial of women with depression, topiramate added to antidepressant treatment produced about 4.2 kg more weight loss than placebo, along with improvements in depression and anger symptoms.26PubMed. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study Case reports have also described successful use in patients with bipolar disorder who gained weight on risperidone.27PubMed Central. Successful use of add-on topiramate for antipsychotic-induced weight gain The appeal here is that topiramate can counteract medication-induced weight gain without undermining the psychiatric treatment that caused it. Few other weight-loss agents have been tested in these populations as directly.
Blood Pressure, Blood Sugar, and Other Metabolic Benefits
Weight loss from topiramate does not just change the number on the scale. In the 60-week obesity trial, topiramate at 192 mg per day reduced systolic blood pressure by about 5.7 mmHg and diastolic by about 3.4 mmHg, along with improvements in glucose and insulin levels. Even the lowest tested dose (96 mg) showed blood pressure reductions compared to a slight increase in the placebo group.28International Journal of Obesity. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
In people with type 2 diabetes already taking metformin, adding topiramate at 192 mg per day led to a 6.5% body weight reduction and a 0.6% absolute drop in HbA1c, along with significant decreases in systolic blood pressure.29International Journal of Obesity. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study A 0.6% HbA1c reduction is clinically relevant; it is in the same ballpark as adding a second diabetes drug. For someone whose weight, blood pressure, and blood sugar are all elevated, topiramate addresses multiple problems at once, which is part of why it keeps getting studied despite never becoming a mainstream weight-loss prescription.
The Dose Sweet Spot
The data consistently shows diminishing returns at higher doses. Going from 96 mg to 192 mg per day adds about two percentage points of body weight loss, but going from 192 mg to 256 mg adds less than one percentage point while substantially increasing the side-effect burden.30International Journal of Obesity. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects The most common adverse events during titration involved the nervous system: tingling in the hands and feet (paresthesia), trouble concentrating, memory problems, mood changes, and feeling mentally slowed down. Most of these emerged during the dose-increase phase rather than at a stable dose.
In the combination product Qsymia, the topiramate dose is kept lower (46 mg or 92 mg in the extended-release formulation) and paired with phentermine, a strategy designed to get more weight loss with fewer cognitive side effects than high-dose topiramate alone. This is worth knowing if you are discussing options with your doctor: the combination at a moderate topiramate dose may give you a better trade-off than pushing topiramate solo to the upper ranges. Either way, the standard approach is to start low, increase gradually over several weeks, and back off if side effects become disruptive.